CIAS
BIO icon

CFS Investment Advisory Services’s Bio-Rad Laboratories Class A BIO Stock Holding History

CFS Investment Advisory Services’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39,989
Closed – – 242
2022
Q1 		$0 Buy
+39,989
New +$24.1M ﹤0.01% 426

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CFS Investment Advisory Services's BIO Position: Q2 2022 in Review

CFS Investment Advisory Services sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 39,989 shares.

CFS Investment Advisory Services first reported a position in BIO in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

  • CFS Investment Advisory Services reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
  • CFS Investment Advisory Services sold 39,989 Bio-Rad Laboratories Class A shares in Q2 2022.
  • CFS Investment Advisory Services first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 1 quarter.
  • CFS Investment Advisory Services's Bio-Rad Laboratories Class A position peaked at $0 in Q1 2022.
  • 500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on CFS Investment Advisory Services's 13F filing for Q2 2022, filed 16 Aug 2022.